1. Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
- Author
-
John Mitrofanis, Sharon Tilley, Ann Liebert, Parastoo Jalilitabaei, Gillian Z. Heller, Hosen Kiat, Brian Bicknell, and E-Liisa Laakso
- Subjects
medicine.medical_specialty ,Parkinson's disease ,Motor symptoms ,Disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Randomized controlled trial ,law ,medicine ,Humans ,Prospective Studies ,Low-Level Light Therapy ,Prospective cohort study ,RC346-429 ,030304 developmental biology ,Mobility ,0303 health sciences ,business.industry ,SARS-CoV-2 ,Minimal clinically important difference ,Incidence (epidemiology) ,Research ,COVID-19 ,Sequela ,Parkinson Disease ,General Medicine ,Photobiomodulation ,medicine.disease ,Fine motor skill ,Clinical trial ,Coronavirus ,Physical therapy ,Parkinson’s disease ,Neurology (clinical) ,Neurosurgery ,Neurology. Diseases of the nervous system ,business ,030217 neurology & neurosurgery - Abstract
Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p, registered on 12/01/2018.
- Published
- 2021